Docetaxel Axios 20 mg/vial (IV Infusion)

20 mg vial: ৳ 4,400.00

Medicine Details

Category	Details
Generic	Docetaxel trihydrate
Company	Bots pvt limited
Also available as	Docetaxel axios 80 mg injection

Docetaxel Axios is an antineoplastic agent indicated for the treatment of various types of cancer, including Breast Cancer (BC), Non-small Cell Lung Cancer (NSCLC), Castration-Resistant Prostate Cancer (CRPC), Gastric Adenocarcinoma (GC), and Squamous Cell Carcinoma of the Head and Neck (SCCHN). It acts by disrupting the microtubular network in cells, thereby inhibiting mitosis and cell division. The dosage and administration depend on the type of cancer being treated and may require premedication with oral corticosteroids. It is a CYP3A4 substrate and should be stored between 2°C and 25°C, protected from light.

Administer intravenously (IV) over 1 hr every 3 weeks. PVC equipment is not recommended. Use only a 21 gauge needle to withdraw docetaxel from the vial. The dosage varies for different types of cancer, such as Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer, Gastric Adenocarcinoma, and Squamous Cell Carcinoma of the Head and Neck. Premedication with oral corticosteroids is required, and the dose should be adjusted as needed.

Indicated for locally advanced or metastatic Breast Cancer (BC) after chemotherapy failure; with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC; for locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) after platinum therapy failure; with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC; in metastatic Castration-Resistant Prostate Cancer (CRPC) with prednisone; with cisplatin and fluorouracil for untreated, advanced Gastric Adenocarcinoma (GC), including the gastroesophageal junction; with cisplatin and fluorouracil for induction treatment of locally advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN).

Acts by disrupting the microtubular network in cells that is essential for vital mitotic and interphase cellular functions. Promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. Binds to free tubulin, decreasing the critical intracellular concentration of tubulin. Leads to the inhibition of mitosis in cells.

Docetaxel is a CYP3A4 substrate. In vitro studies have shown that its metabolism may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4.

Contraindicated in patients with neutrophil counts of <1500 cells/mm³ and a history of severe hypersensitivity reactions to docetaxel or to other drugs formulated with polysorbate 80. Severe reactions, including anaphylaxis, have occurred.

Common adverse reactions include infections, neutropenia, anemia, febrile neutropenia, hypersensitivity, thrombocytopenia, neuropathy, dysgeusia, dyspnea, constipation, anorexia, nail disorders, fluid retention, asthenia, pain, nausea, diarrhea, vomiting, mucositis, alopecia, skin reactions, and myalgia. Incidence varies depending on the indication.

Docetaxel can cause fetal harm when administered to a pregnant woman. There is no information regarding its presence in human milk, or on its effects on milk production or the breastfed child. No lactation studies in animals have been conducted.

Should be administered under the supervision of a physician experienced in the use of antineoplastic agents. There is a higher risk of developing severe adverse reactions in patients with hepatic impairment. Therapy should not be given to patients with neutrophil counts of less than 1,500 cells/mm³. Severe hypersensitivity reactions, acute myeloid leukemia, and fatal cases of enterocolitis have been reported.

There is no known antidote for docetaxel overdose. In case of overdose, the patient should be kept in a specialized unit and vital functions closely monitored. Exacerbation of adverse events may be expected, with primary anticipated complications consisting of bone marrow suppression, peripheral neurotoxicity, and mucositis.

Store between 2°C and 25°C and protected from light. Freezing does not adversely affect the product.